梯瓦制药 TEVA 深 沪
已收盘 10-10 16:00:00 美东时间
20.03
-0.010
-0.05%
华盛通- 最 高20.05
- 今 开20.00
- 成交量 820.44万股
- 最 低 19.77
- 昨 收 20.04
- 总市值 229.74亿
- 52周最高 22.80
- 市盈率 静 --
- 换手率 0.72%
- 52周最低 12.465
- 委 比 75.43%
- 总股本 11.47亿
- 历史最高 69.8535
- 量 比 0.86
- 振 幅 1.40%
- 历史最低 6.07
- 每 手 1
- 风险率 1.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Teva Pharmaceuticals Announces FDA Approves UZEDY As First Subcutaneous Long-Acting Risperidone For Maintenance Treatment Of Bipolar I Disorder And Schizophrenia
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in
10-11 03:01
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder
The U.S. FDA has approved UZEDY ® (risperidone) extended-release injectable suspension for the maintenance treatment of bipolar I disorder (BD-I) and schizophrenia in adults. This long-acting formulation, utilizing SteadyTeq™ technology, allows steady drug release and provides three monthly dosing options (50 mg, 75 mg, and 100 mg). UZEDY aims to address unmet needs by improving treatment adherence and reducing relapses in these patient populatio...
10-10 19:00
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation.
10-06 20:55
美股大行评级 | 潜在涨幅1176.6%！Ascendiant Capital上调Society Pass目标价至18美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从15美元升至18美元；Ascendiant Capital：维持Surgepays"买入"评级，目标价从9美元升至9.5美元
10-06 08:35
FDA introduces program to expedite review of domestic generic drugs
The U.S. Food and Drug Administration has introduced a new pilot program aimed at accelerating the review process for generic drugs that are both tested and produced entirely within the United States....
10-04 03:05
JP Morgan Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $26
JP Morgan analyst Chris Schott maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $23 to $26.
10-03 20:21
国金医药甘坛焕丨恩华药业深度：自研新药报产迎破局，创新步入收获期
（来源：国金证券研究所） 作者：甘坛焕 摘要 麻龙头再起航，高壁垒产品助增长。(1)历久弥新，公司历年总营收及归母净利润均保持稳健增长，过去十年（2...
09-26 16:33
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
